Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABA<sub>A</sub> receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A<sub>1</sub> and A<sub>2</sub> subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R. Squibb and Sons in the 1970s.